Latest Options News

Nyrada Inc. reported a $3.19 million loss for the half-year ending December 2025, while advancing its lead drug candidate Xolatryp® into Phase IIa clinical trials targeting heart attack treatment.

Livium Ltd has turned a profit in the first half of FY26 despite lower revenues, supported by cost cuts and a new joint venture. The company also secured $4.5 million in fresh capital to expand its lithium-ion battery recycling and rare earth initiatives.

Albright Metals has agreed to sell a significant portion of its Bryah Basin tenements to Catalyst Metals for $1 million cash plus $800,000 in shares, enabling a sharper focus on its Canadian gold and antimony projects.

BlueScope has received a revised takeover proposal offering $32.35 per share in cash from a consortium of SGH and Steel Dynamics, prompting the Board to reassess the offer amid strategic restructuring plans.

Star Minerals has entered a strategic partnership with Catalyst Metals, securing a gold milling agreement for its Tumblegum South project and selling its West Bryah Basin copper-gold assets for $2.75 million. Catalyst also commits to a $1 million equity placement in Star Minerals, underpinning the company’s development plans.

St George Mining has reported exceptional drilling results at its Araxá Rare Earths and Niobium Project in Brazil, including a record 164.45m mineralised intercept from surface. These results expand the known resource footprint well beyond current estimates, signalling significant growth potential.

QEM Limited has raised $1.442 million through a well-supported placement to fund a strategic review of its flagship Julia Creek Vanadium and Energy Project and explore new critical minerals opportunities.

Vicinity Centres reported a strong first half of FY26 with a statutory net profit of $805.6 million, strategic acquisitions including full ownership of Uptown Brisbane, and reaffirmed guidance for the full year.

Identitii Limited faces a setback as Beauvais Capital terminates its underwriting agreement following Takeovers Panel orders, triggering shareholder withdrawal rights and uncertainty over the company’s capital raising plans.

Starpharma reports a $1.37 million profit for H1 FY26, driven by a major upfront payment from Genentech and progress in its radiopharmaceutical pipeline. The biotech also expands its consumer health footprint amid growing partnerships.

Euro Manganese Inc. reported progress on its Chvaletice and Bécancour manganese projects, securing funding amendments and advancing permitting despite ongoing financial pressures. The company is positioned to benefit from growing demand for high-purity manganese in lithium-ion batteries amid evolving market dynamics.

Euro Manganese Inc. reported a net loss of $3.6 million for Q3 2025 and extended key financing milestones to June 2026, highlighting ongoing challenges in funding its Chvaletice Manganese Project.